CLLS - Cell therapy biotech Vor Biopharma prices upsized IPO at $18/share trades today
Vor Biopharma (VOR) has priced its initial public offering of ~9.83M shares at $18/share, for gross proceeds of ~$176.9M.The company originally planned to offer 8.8M shares at a price range of $16-$18.Underwriters' over-allotment is an additional 1,474,202 shares. Shares to kick-off trading today on Nasdaq.Offering is expected to close on February 9.The company's pipeline contains its lead engineered hematopoietic stem cell (eHSC) candidate, VOR33, and its companion therapeutic, VCAR33, a CAR-T therapy designed to target CD33. A T cell therapy using the same CAR construct as VCAR33 is currently in a Phase 1/2 trial for AML that is sponsored by the National Marrow Donor Program, with initial monotherapy proof-of-concept data expected in 2022. The company's IND application for VOR33 in patients with AML was accepted by the FDA in January 2021, and it intends to initiate a Phase 1/2a trial in the 1H21.The company faces competition from the vendors that provide or are
For further details see:
Cell therapy biotech Vor Biopharma prices upsized IPO at $18/share, trades today